Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Oct;21(7):1152-65.
doi: 10.1111/resp.12780. Epub 2016 Mar 30.

Acute exacerbation of COPD

Affiliations
Review

Acute exacerbation of COPD

Fanny W Ko et al. Respirology. 2016 Oct.

Abstract

The literature of acute exacerbation of chronic obstructive pulmonary disease (COPD) is fast expanding. This review focuses on several aspects of acute exacerbation of COPD (AECOPD) including epidemiology, diagnosis and management. COPD poses a major health and economic burden in the Asia-Pacific region, as it does worldwide. Triggering factors of AECOPD include infectious (bacteria and viruses) and environmental (air pollution and meteorological effect) factors. Disruption in the dynamic balance between the 'pathogens' (viral and bacterial) and the normal bacterial communities that constitute the lung microbiome likely contributes to the risk of exacerbations. The diagnostic approach to AECOPD varies based on the clinical setting and severity of the exacerbation. After history and examination, a number of investigations may be useful, including oximetry, sputum culture, chest X-ray and blood tests for inflammatory markers. Arterial blood gases should be considered in severe exacerbations, to characterize respiratory failure. Depending on the severity, the acute management of AECOPD involves use of bronchodilators, steroids, antibiotics, oxygen and noninvasive ventilation. Hospitalization may be required, for severe exacerbations. Nonpharmacological interventions including disease-specific self-management, pulmonary rehabilitation, early medical follow-up, home visits by respiratory health workers, integrated programmes and telehealth-assisted hospital at home have been studied during hospitalization and shortly after discharge in patients who have had a recent AECOPD. Pharmacological approaches to reducing risk of future exacerbations include long-acting bronchodilators, inhaled steroids, mucolytics, vaccinations and long-term macrolides. Further studies are needed to assess the cost-effectiveness of these interventions in preventing COPD exacerbations.

Keywords: aetiology; chronic obstructive pulmonary disease; diagnosis; exacerbation; intervention.

PubMed Disclaimer

References

    1. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, et al. International variation in the prevalence of COPD (the BOLD study): a population‐based prevalence study. Lancet 2007; 370: 741‐50. - PubMed
    1. Ko FW, Hui DS, Lai CK. Worldwide burden of COPD in high‐ and low‐income countries. Part III. Asia‐Pacific studies. Int. J. Tuberc. Lung Dis. 2008; 12: 713‐7. - PubMed
    1. Global Initiative for Chronic Obstructive Lung Disease . Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease. Updated 2015. [Accessed 12 Jun 2015]. Available from URL:http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015_Apr2.pdf
    1. Lim S, Lam DC, Muttalif AR, Yunus F, Wongtim S, Lan le TT, Shetty V, Chu R, Zheng J, Perng DW, et al. Impact of chronic obstructive pulmonary disease (COPD) in the Asia‐Pacific region: the EPIC Asia population‐based survey. Asia Pac. Fam. Med. 2015; 14: 4. - PMC - PubMed
    1. Suzuki M, Makita H, Ito YM, et al. Clinical features and determinants of COPD exacerbation in the Hokkaido COPD cohort study. Eur. Respir. J. 2014; 43: 1289‐97. - PubMed

MeSH terms